GlassScriptPhysician profile
Muhammad Shamim
NPI 1699303610
$739.24
in general payments reported to CMS, 2019-2025
11 companies · $420 in 2025
The $420 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.20 · 2023: $18.81 · 2024: $236 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.41 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $144.63 | 2025 | |
| Amgen INC. | $84.34 | 2024-2025 | Evenity, Otezla, Tavneos |
| Cardiovascular Systems INC. | $64.20 | 2021 | |
| Janssen Biotech, INC. | $48.47 | 2024-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $40.14 | 2023-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $32.20 | 2025 | Saphnelo |
| Glaxosmithkline, LLC. | $30.38 | 2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.28 | 2025 | Ofev |
| Lilly USA, LLC | $20.03 | 2024 | Taltz |
| Genentech USA, INC. | $15.16 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shamim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.